Latest Pharvaris News & Updates

See the latest news and media coverage for Pharvaris. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Pharvaris

Biopharmaceutical company developing oral therapies for hereditary angioedema

pharvaris.com
Headquarters
Zug, Switzerland
Founded year
2015
Company type
Public company
Number of employees
190–200
Industry
Pharmaceuticals

Last updated

Latest news about Pharvaris

In short: Pharvaris reported positive Phase 3 results for once-daily oral deucrictibant XR in HAE prevention.

Company announcements

Pharvaris

Pharvaris reports long-term deucrictibant efficacy in CHAPTER-1

Final Phase 2 open-label extension data show a 92.4% average attack reduction and about half of participants attack-free over up to ~34 months, with no safety signals.

Unlock all announcements with a

Media coverage

Yahoo Finance

Pharvaris Shares Surge 27% After Deucrictibant Phase 3 Trial Meets Primary Endpoint

Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline...

Unlock all articles with a

Never miss news about Pharvaris

Track Pharvaris and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.